Cerecor Inc (CERC) Director Buys $23,739.60 in Stock

Share on StockTwits

Cerecor Inc (NASDAQ:CERC) Director Armistice Capital, Llc bought 6,504 shares of the company’s stock in a transaction on Monday, January 7th. The stock was bought at an average cost of $3.65 per share, for a total transaction of $23,739.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Armistice Capital, Llc also recently made the following trade(s):

  • On Friday, January 4th, Armistice Capital, Llc acquired 20,000 shares of Cerecor stock. The stock was acquired at an average cost of $3.42 per share, with a total value of $68,400.00.
  • On Tuesday, December 31st, Armistice Capital, Llc acquired 12,300 shares of Cerecor stock. The stock was bought at an average cost of $3.18 per share, with a total value of $39,114.00.
  • On Saturday, December 28th, Armistice Capital, Llc purchased 26,499 shares of Cerecor stock. The stock was bought at an average price of $3.12 per share, for a total transaction of $82,676.88.
  • On Monday, December 31st, Armistice Capital, Llc purchased 12,300 shares of Cerecor stock. The shares were purchased at an average cost of $3.18 per share, with a total value of $39,114.00.
  • On Friday, December 28th, Armistice Capital, Llc acquired 26,499 shares of Cerecor stock. The shares were purchased at an average price of $3.12 per share, with a total value of $82,676.88.
  • On Monday, December 17th, Armistice Capital, Llc acquired 14,938 shares of Cerecor stock. The stock was acquired at an average price of $3.26 per share, for a total transaction of $48,697.88.
  • On Friday, December 14th, Armistice Capital, Llc acquired 28,032 shares of Cerecor stock. The shares were bought at an average cost of $3.33 per share, for a total transaction of $93,346.56.
  • On Monday, December 10th, Armistice Capital, Llc bought 13,815 shares of Cerecor stock. The shares were acquired at an average price of $3.36 per share, with a total value of $46,418.40.
  • On Thursday, December 6th, Armistice Capital, Llc bought 16,400 shares of Cerecor stock. The stock was bought at an average cost of $3.44 per share, with a total value of $56,416.00.
  • On Monday, December 3rd, Armistice Capital, Llc bought 19,495 shares of Cerecor stock. The stock was purchased at an average cost of $3.50 per share, with a total value of $68,232.50.

Shares of NASDAQ CERC opened at $3.89 on Friday. Cerecor Inc has a 12 month low of $2.18 and a 12 month high of $5.74. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.74 and a quick ratio of 0.70. The stock has a market cap of $154.25 million, a price-to-earnings ratio of 9.26 and a beta of 1.30.

Cerecor (NASDAQ:CERC) last announced its earnings results on Tuesday, November 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.14). Cerecor had a negative net margin of 241.29% and a negative return on equity of 75.94%. The business had revenue of $4.08 million for the quarter, compared to analysts’ expectations of $4.80 million. On average, sell-side analysts predict that Cerecor Inc will post -1.09 earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc increased its position in Cerecor by 10.1% in the third quarter. Vanguard Group Inc now owns 87,929 shares of the company’s stock worth $411,000 after buying an additional 8,094 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Cerecor in the 3rd quarter valued at $169,000. Finally, BlackRock Inc. boosted its position in shares of Cerecor by 630.4% in the 2nd quarter. BlackRock Inc. now owns 27,520 shares of the company’s stock worth $120,000 after purchasing an additional 23,752 shares in the last quarter. 44.48% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have recently weighed in on CERC. TheStreet raised shares of Cerecor from a “d” rating to a “c” rating in a research report on Monday, November 12th. ValuEngine raised shares of Cerecor from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Finally, LADENBURG THALM/SH SH assumed coverage on shares of Cerecor in a research note on Thursday, December 20th. They issued a “buy” rating and a $9.00 price objective for the company.

ILLEGAL ACTIVITY WARNING: This report was first reported by Macon Daily and is the property of of Macon Daily. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://macondaily.com/2019/01/11/cerecor-inc-cerc-director-buys-23739-60-in-stock.html.

About Cerecor

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation.

Featured Story: Technical Analysis of Stocks, How Can It Help

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply